Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: a simulation study

被引：0
|
作者：
Michela Del Prete
François-Alexandre Buteau
Jean-Mathieu Beauregard
机构：
[1] Université Laval,Department of Radiology and Nuclear Medicine, and Cancer Research Center
[2] CHU de Québec – Université Laval,Department of Medical Imaging, and Oncology Branch of Research Center
来源：
European Journal of Nuclear Medicine and Molecular Imaging | 2017年 / 44卷
关键词：
Personalized; Peptide receptor radionuclide therapy; Lu-octreotate; Dosimetry; Neuroendocrine tumours;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1490 / 1500
页数：10
相关论文
共 50 条
  • [1] Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: a simulation study
    Del Prete, Michela
    Buteau, Francois-Alexandre
    Beauregard, Jean-Mathieu
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (09) : 1490 - 1500
  • [2] Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial
    Michela Del Prete
    François-Alexandre Buteau
    Frédéric Arsenault
    Nassim Saighi
    Louis-Olivier Bouchard
    Alexis Beaulieu
    Jean-Mathieu Beauregard
    European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46 : 728 - 742
  • [3] Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial
    Del Prete, Michela
    Buteau, Francois-Alexandre
    Arsenault, Frederic
    Saighi, Nassim
    Bouchard, Louis-Olivier
    Beaulieu, Alexis
    Beauregard, Jean-Mathieu
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (03) : 728 - 742
  • [4] Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours
    Samer Ezziddin
    Feras Khalaf
    Maria Vanezi
    Torjan Haslerud
    Karin Mayer
    Abdullah Al Zreiqat
    Winfried Willinek
    Hans-Jürgen Biersack
    Amir Sabet
    European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41 : 925 - 933
  • [5] Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours
    Ezziddin, Samer
    Khalaf, Feras
    Vanezi, Maria
    Haslerud, Torjan
    Mayer, Karin
    Al Zreiqat, Abdullah
    Willinek, Winfried
    Biersack, Hans-Juergen
    Sabet, Amir
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 (05) : 925 - 933
  • [6] Personalized 177Lu-Octreotate Peptide Receptor Radionuclide Therapy (PRRT) Allows a Safe and Significant Increase of Radiation Dose to Neuroendocrine Tumors (NETs)
    Del Prete, M.
    Buteau, F. A.
    Beauregard, J. M.
    NEUROENDOCRINOLOGY, 2016, 103 : 92 - 92
  • [7] 177Lu-octreotate therapy for neuroendocrine tumours is enhanced by Hsp90 inhibition
    Hofving, Tobias
    Sandblom, Viktor
    Arvidsson, Yvonne
    Shubbar, Emman
    Altiparmak, Gulay
    Swanpalmer, John
    Almobarak, Bilal
    Elf, Anna-Karin
    Johanson, Viktor
    Elias, Erik
    Kristiansson, Erik
    Forssell-Aronsson, Eva
    Nilsson, Ola
    ENDOCRINE-RELATED CANCER, 2019, 26 (04) : 437 - 449
  • [8] Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours
    Claringbold, Phillip G.
    Brayshaw, Paul A.
    Price, Richard A.
    Turner, J. Harvey
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 (02) : 302 - 311
  • [9] Neuroradiological and Neuropathological Changes After 177Lu-Octreotate Peptide Receptor Radionuclide Therapy of Refractory Esthesioneuroblastoma
    Schneider, Julia R.
    Shatzkes, Deborah R.
    Scharf, Stephen C.
    Tham, Tristan M.
    Kulason, Kay O.
    Buteau, Francois-Alexandre
    Del Prete, Michela
    Chakraborty, Shamik
    Anderson, Todd A.
    Asiry, Saeed
    Beauregard, Jean-Mathieu
    Langer, David J.
    Costantino, Peter D.
    Boockvar, John A.
    OPERATIVE NEUROSURGERY, 2018, 15 (06) : E100 - E109
  • [10] Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours
    Phillip G. Claringbold
    Paul A. Brayshaw
    Richard A. Price
    J. Harvey Turner
    European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38 : 302 - 311
12345